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Isolation of Angiopoietin-1,
a Ligand for the TIE2 Receptor,
by Secretion-Trap Expression Cloning
Samuel Davis, Thomas H. Aldrich, Pamela F. Jones, Flt-4, and Flk-1/KDR, all of which are members of the
vascular endothelial growth factor (VEGF) receptor fam-Ann Acheson, Debra L. Compton, Vivek Jain,
ily. The requisite roles of Flt-1 and Flk-1 during vascularTerence E. Ryan, Joanne Bruno,
development, as well as that of VEGF, have been con-Czeslaw Radziejewski, Peter C. Maisonpierre,
firmed by analysis of genetically engineered mice lack-and George D. Yancopoulos
ing these proteins (Fong et al., 1995; Shalabyet al., 1995;Regeneron Pharmaceuticals, Inc.
Carmeliet et al., 1996; Ferrara et al., 1996). The more777 Old Saw Mill River Road
recently discovered TIE receptor family (Dumont et al.,Tarrytown, New York 10591
1992; Partanen et al., 1992; Iwama et al., 1993; Maison-
pierre et al., 1993; Sato et al., 1993; Schnurch and Risau,
1993; Ziegler et al., 1993), consisting of TIE1 and TIE2Summary
(also termed Tek), also have been found to be critically
involved in the formation of vasculature (Dumont et al.,TIE2 is a receptor-like tyrosine kinase expressed al-
1994; Puri et al., 1995; Sato et al., 1995). Mice deficientmost exclusively in endothelial cells and early hemo-
in TIE1 die between embryonic day 13.5 (E13.5) andpoietic cells and required for the normal development
birth and display edema and hemmorhage resulting fromof vascular structures during embryogenesis. We re-
poor structural integrity of the endothelial cells (Puri etport the identification of a secreted ligand for TIE2,
al., 1995; Sato et al., 1995). In contrast, mice deficienttermed Angiopoietin-1, using a novel expression clon-
in TIE2 have an earlier lethal phenotype and die by E10.5ing technique that involves intracellular trapping and
(Dumont et al., 1994; Sato et al., 1995). The most promi-detection of the ligand in COS cells. The structure of
nent defects observed in these mice include the failureAngiopoietin-1 differs from that of known angiogenic
of the endothelial lining of the heart to develop properly,factors or other ligands for receptor tyrosine kinases.
the failure of remodelling of the primary capillary plexusAlthough Angiopoietin-1 binds and induces the tyro-
into large and small vessels, and the lack of capillarysine phosphorylation of TIE2, it does not directly pro-
sprouts into the neuroectoderm. In addition to their ex-mote the growth of cultured endothelial cells. How-
pression by endothelial cells, the TIEs are also specifi-ever, its expression in close proximity with developing
cally expressed in early hemopoietic stem cells (Iwamablood vessels implicates Angiopoietin-1 in endothelial
et al., 1993; Batard et al., 1996; Hashiyama et al., 1996),developmental processes.
perhaps reflecting the origin of both lineages from a
common hemangioblast precursor (Shalaby et al.,1995);
Introduction however, the early death of mice lacking the TIEs has
limited the use of these mice in elucidating the precise
Embryonic vascular development involves a complex roles of the TIEs in hemopoiesis (Rodewald and Sato,
series of events during which endothelial cells differenti- 1996). Because the TIE receptor family is critically in-
ate, proliferate, migrate, and undergo morphologic or- volved in angiogenesis and may play a role in hemopoie-
ganization in the context of their surrounding tissues sis as well, we initiated a search for ligands that may
(Risau, 1991, 1995). Vascular development is generally activate these receptors. Here we describe the use of a
classified into two successive phases. The first, known novel expression cloning strategy to identify a secreted
as vasculogenesis, refers to the process whereby newly ligand for the TIE2 receptor, which we designate Angio-
differentiated endothelial cells spontaneously coassem- poietin-1 to reflect not only its requisite role in angiogen-
ble into tubules that fuse to form a rather homogeneous esis (Suri et al., 1996 [this issue of Cell]) but also its
primary vasculature in the embryo. Subsequent remod- potential actions during hemopoiesis.
eling of this primary vascular network into large and Searches for the ligands for orphan receptors have
small vessels brings into play a different process, termed traditionally proceeded by several routes, depending on
angiogenesis. Angiogenesis in the embryo also leads to the type of ligand that is sought. In the case of secreted
the sprouting of vessels into initially avascular organs, ligands, two major approaches have been used. The
such as the brain. In the adult, angiogenesis accounts first uses soluble forms of the receptors to effect affinity
for neovascularization that accompanies the normal purification of the ligands, followed by protein sequenc-
processes of ovulation, placental development, and ing and cloning of cDNAs containing the desired pep-
wound healing, as well as various clinically significant tides (e.g., Stitt et al., 1995). Alternatively, expression
pathologic processes such as tumor growth and dia- cloning strategies involve the construction and screen-
betic retinopathy (Ferrara, 1995; Folkman, 1995; Hana- ing of “pooled expression libraries” (e.g., Lok et al.,
han and Folkman, 1996). 1994). In these strategies, many small pools of cDNAs
Intercellular signaling mechanisms that govern the are individually transfected into cells, and conditioned
formation of blood vessels have only recently begun to media from the individual transfections are then sep-
be studied at the molecular level. Two families of recep- arately assayed for their ability to produce activities that
tor tyrosine kinases have been identified whose expres- stimulate receptor-bearing reporter cells. A sensitive
sion is largely restricted to endothelial cells and which and simple assay must be available, since tens of thou-
are essential for normal development of blood vessels sands of pools often must be screened, particularly if
the desired cDNA is present only at low abundance.(Mustonen and Alitalo, 1995). One family includes Flt-1,
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Less labor-intensive approaches, such as those based
on the yeast two-hybrid system for cloning interacting
partners (Chien et al., 1991), cannot be used since
growth factor–receptor binding depends on a large in-
teracting surface between two essentially full-length and
correctly folded proteins (de Vos et al., 1992), the folding
of which depends on correct disulfide pairing, which
usually occurs efficiently only during secretion from
mammalian cells. The yeast two-hybrid system takes
advantage of interactions between short stretches of
peptides that can occur within the reducing environment
found within the yeast cell cytoplasm.
The expression cloning of cDNAs encoding mem-
brane-bound (as opposed to secreted) ligands for or-
phan receptors has been far easier. Transfection of en-
tire cDNA libraries into large numbers of cells can be
used and still allow very rapid screening, since an indi-
vidual cell containing the desired cDNA is uniquely
marked on its surface by expression of the desired li-
gand. This rare cell can be individually detected within
a background of millions of other cells and thus allows
isolation of the ligand-encoding cDNA (most efficiently
Figure 1. Identification of TIE2 Binding andPhosphorylating Activityby Davis et al., 1994) using soluble and epitope-tagged
in Conditioned Media of C2C12ras Cells and SHEP1–1 Cellsforms of the orphan receptor for the detection by a
(A) BIAcore assay of TIE2 binding activity. Conditioned media (CM)process that is formally identical to methods previously
from each cell line was passed over a BIAcore sensor chip that hadused to clone receptors using epitope-tagged ligands
TIE2-Fccovalently coupled to it. Specificity of binding was assessed
(Davis et al., 1991). Here we introduce an extension of by the inclusion of excess competing soluble TIE2-Fc or TrkB-Fc
this method, termed “secretion-trap expression clon- during the measurement. Binding to the sensor chip is given as
ing,” that allows rapid expression cloning of secreted resonance units (RUs).
(B) Phosphorylation of TIE2 receptor is induced by C2C12ras condi-ligands based only on receptor–ligand binding and that
tioned medium. ABAE cells were either unchallenged (MOCK) orwe have exploited in the isolation of Angiopoietin-1 as
challenged with 10-fold–concentrated conditioned medium froma ligand for the TIE2 receptor. This approach should be
C2C12ras cells that had previously been depleted with either beads
useful not only for isolating ligands for other orphan alone (CM) or with beads coated with TIE2-Fc (CM 1 TIE2-Fc).
receptors but also for identifying interacting partners for Lysates of cells were immunoprecipitated (I.P.) with anti-TIE2 anti-
the plethora of uncharacterized secreted proteins being bodies and analyzed for levels of tyrosine-phosphorylated TIE2 re-
ceptor.discovered in the attempt to sequence the mammalian
genome.
TIE2-Fc (Figure 1B). Despite the detectable binding inResults
their conditioned media, no binding of TIE2-Fc to the
surface of either SHEP1–1 or C2C12ras cells could beIdentification of a Source for a TIE2 Binding
detected, indicating that both cell lines were producingand Phosphorylating Activity
a secreted as opposed to a membrane-bound ligandTo identify potential sources for TIE2 ligands, we con-
for TIE2.structed a probe molecule consisting of the ectodomain
of TIE2 fused to the Fc portion of human IgG1 as well
Secretion-Trap Expression Cloningas control fusion proteins in which the ectodomain of
of a TIE2 LigandTrkB or TIE1 replaced the TIE2 sequences (designated
We have previously shown that receptor-Fc fusion pro-TIE2-Fc, TrkB-Fc, and TIE1-Fc, respectively). These
teins can be effectively used for the expression cloningmolecules were purified and coupled to the surface of
of cDNAs encoding membrane-bound ligands, in partic-a BIAcore sensor chip (as per Stitt et al., 1995), which
ular by using them to surface-label rare ligand-bearingwas then used to screen conditioned media from a vari-
cells individually within a large population of library-ety of cell lines for binding activity that was specific
transfected cells (Davis et al., 1994); after detection offor TIE2. Two cell lines, the human neuroepithelioma
the rare cell expressing the desired ligand on its surface,cell line SHEP1–1 and the mouse myoblast cell line
the cDNA encoding the ligand was rescued from theC2C12ras, were found to have binding activity that could
labeled cell (Davis et al., 1994). We devised an extensionbe competed by the addition of soluble TIE2-Fc but not
of this method (Figure 2A) that would be applicable toTrkB-Fc (Figure 1A). In addition, conditioned media from
secreted ligands, based on the notion that a secretedthese cell lines could induce tyrosine phosphorylation
ligand is, at least temporarily, trapped inside vesicularof the TIE2 receptor in endothelial cells (Figure 1B). The
compartments of the cell until it is exocytosed. We rea-component of the conditionedmedia that induced phos-
soned that if cells were appropriately fixed and perme-phorylation was presumably thesame as the component
abilized, it might bepossible to detect the ligand en routethat specifically bound TIE2-Fc because the phosphory-
lating activity could be depleted by beads coated with to secretion by using the receptor-Fc fusion protein as
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mouse Angiopoietin-1, respectively, since additional re-
lated ligands have also been isolated (P. F. J. et al.,
unpublished data).
The DNA sequence of both the human and mouse
Angiopoietin-1 cDNA clones were determined, revealing
open reading frames encoding 498 amino acids and
sharing 97.6% identity (Figure 3A). Additional cDNA
clones were also derived by hybridization screening of
a human fetal lung library and of a library of the human
cell line T98G. The sequences of all of the human clones
were identical, except that the clone derived from T98G
carried a short three-base deletion, which led to the
deletion of a single glycine residue at position 269 of
the amino acid sequence. RNAse protection assays re-
vealed that mRNAs carrying the three-base deletion
were present as a minority population in all of the RNA
samples examined that were positive for Angiopoietin-1
(data not shown). It is not known whether this deletion
has functional significance. However, the sequence at
the deletion point matches the consensus sequence of
a splice junction after the completion of splicing, so it
seems possible that the deletion is simply a conse-
quence of some type of “exon slippage.”
Figure 2. Secretion-Trap Expression Cloning As expected, there were hydrophobic sequences at
(A) Schematic diagram of the strategy used for expression cloning the N-terminal regions of Angiopoietin-1 typical of se-
of secreted ligands (right), an extension of methods used for expres- cretory signal sequences. Database homology searches
sion cloning of membrane-bound ligands (left).
revealed that the Angiopoietin-1 contained two regions(B) COS cells expressing intracellular Angiopoietin-1 stained with
that bore similarity to known proteins (Figure 3B). TheTIE2-Fc. COS cells depicted were transfected with plasmid DNA
first region, consisting of residues 100–280, showedrescued from a positively stained cell in the primary library screen,
and then stained with TIE2-Fc as described in Experimental Proce- weak homology to myosin and its relatives in the regions
dures; about 20% of the cells are positively stained. of these proteins where they are known to possess
coiled-coil quaternary structure. An analysis of the
amino acid sequence, using algorithms developed to
an immunohistochemical probe. This approach would estimate the probability of coiled-coil structure in a given
allow the identification of rarecells expressing the ligand protein sequence, revealed a high probability of coiled-
within a large population of cells transfected with an coil structure in this region. The second region, con-
expression library; plasmid DNA encoding the ligand sisting of residues 280–498, had strong similarity to a
could then be directly rescued from these rare cells. family of proteins, including fibrinogen, tenascin, hfrep,
cDNA expression libraries were constructed from hu- ficolin, and the Drosophila protein SCABROUS, that
man SHEP1–1 and mouse C2C12ras cells, both of which share a region of homology about 200 amino acids long
aresources of TIE2 ligand, and werescreened according (Figure 3C).
to the strategy outlined above. In each case, rare cells
(z1 in 106) were identified when COS cells transfected
with the libraries were stained with TIE2-Fc fusion pro- Biochemical Characterization of Angiopoietin-1
To examine the biochemical properties of Angiopoie-teins. For each of these stained cells, plasmid DNA was
rescued, electroporated into bacterial cells, and ampli- tin-1, we expressed it in COS cellsand studied thecondi-
tioned media produced by the transfected cells. West-fied to produce an enriched pool of much lower com-
plexity than the original library; each of these primary ern blot analysis revealed that Angiopoietin-1 was a 70
kDa protein, larger than would be predicted from itspools of plasmids was then used to retransfect COS
cells. In contrast to the rare TIE2-Fc stained cells seen amino acid sequence (Figure 4A). Because thesequence
contained several potential glycosylation sites, we ex-following library transfections, cells transfected with the
primary pools displayed many TIE2-Fc stained cells, as amined the effect of treatment with PNGase-F, which
removes sugar residues. This treatment did indeed re-shown in Figure 2B (each with the typical appearance of
intra-Golgi staining, as would be expected for a protein duce the molecular weight to the expected z55 kDa,
thus confirming that Angiopoietin-1 is a glycoproteindetected en route to secretion), demonstrating that con-
siderable enrichment for plasmids encoding TIE2 li- (Figure 4A).
To determine whether recombinant Angiopoietin-1gands had been achieved. Examination of individual
plasmids derived from the primary pools revealed that could bind in secreted form to the TIE2 receptor, we
examined conditioned media from COS cells trans-a high percentage were positive for TIE2-Fc staining
following transfection into COS cells and therefore con- fected with Angiopoietin-1 cDNAs for binding activity
on BIAcoresensor chips coupled to TIE2-Fc, TIE1-Fc, ortained cDNAs encoding either human (from SHEP1–1
cells) or mouse (from C2C12ras cells) versions of a li- TrkB-Fc. Angiopoietin-1–containing conditioned media
displayed binding activity only to the TIE2-Fc surfacegand for TIE2. We designate these ligands human and
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Figure 3. Sequence Analysis of Angiopoietin-1
(A) Comparison of human and mouse Angiopoietin-1. Asterisk, variable glycine.
(B) Schematic diagram of the structure of Angiopoietin-1. The coiled-coil domain begins approximately 50 amino acids from the beginning
of the mature protein.
(C) Comparison of the fibrinogen-like domain of Angiopoietin-1 with homologous domains of related proteins.
(Figure 4B), and this binding could be competed only proliferative potency of several of these factors with the
effects of Angiopoietin-1 on cultured endothelial cells.with the simultaneous addition of excess soluble TIE2-
Fc but not TrkB-Fc or TIE1-Fc (Figure 4B), together dem- When human endothelial cells were treated with basic
fibroblast growth factor, VEGF, or epidermal growth fac-onstrating that Angiopoietin-1 is specific for TIE2. The
binding affinity was estimated at KD 5 3.7 nM based tor, proliferation was readily induced (Figure 5A and data
not shown). However, under the same culture condi-on an assay in which the ligand was immobilized on
nitrocellulose and probed with varying amounts of TIE2- tions, concentrations of Angiopoietin-1 that are higher
than necessary to induce robust tyrosine phosphoryla-Fc (Figure 4C).
To examine whether cloned Angiopoietin-1 could in- tion of TIE2 did not elicit a detectable growth response
(Figure 5B). In another assay typically used to evaluateduce tyrosine phosphorylation of TIE2, we challenged
bovine and human endothelial cells with COS cell condi- angiogenic factors, in which factors such as basic fibro-
blast growth factor or VEGF induce endothelial cell tu-tioned media containing Angiopoietin-1. Angiopoietin-1
could induce tyrosine phosphorylation of TIE2 in all of bules to form within collagen matrices, chronic addition
of Angiopoietin-1 was unable to induce tubule formationthe endothelial cell lines examined (Figures 4D and 4E),
and this induction could be blocked by the addition of (data not shown).
Because Angiopoietin-1 did not appear to display theexcess soluble TIE2-Fc but not TrkB-Fc (Figure 4D).
Thus, recombinant Angiopoietin-1 both binds and acti- biologic activities typical of other endothelial cell growth
factors, we decided to verify that other ways of activat-vates TIE2.
ing theTIE2 catalytic domain also did not lead to prolifer-
ative responses. We thus constructed a chimeric recep-Angiopoietin-1 Does Not Induce Growth
Responses in Endothelial Cells tor consisting of the ectodomain of TrkC fused to the
cytoplasmic domain of TIE2, which thereby allowed acti-Factors involved in angiogenesis often have proliferative
effects on cultured endothelial cells. We compared the vation of the TIE2 kinase domain following NT3 addition
Angiopoietin-1, a Ligand for the TIE2 Receptor
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FGF (Figure 5C). In contrast, when treated with NT3, the
TrkC cells proliferated, whereas the TrkC/TIE2 cells did
not (Figure 5D), even though tyrosine phosphorylation
of the chimeric receptor was clearly induced in these
cells by NT3 (Figure 5D, inset).
Taken together, our results indicate that Angiopoie-
tin-1 activation of TIE2 does not induce the typical
growth responses seen with other endothelial cell
growth factors, suggesting that it may have actions that
are not revealed by classic in vitro assays previously
used to characterize endothelial growth factors. Consis-
tent with this possibility, in an accompanying article (Suri
et al., 1996) we report that disruption of the Angiopoie-
tin-1 gene leads to distinctive defects in embryonic vas-
cular development unlike those seen in embryos lacking
VEGF (but similar to those in embryos lacking TIE2),
suggesting that Angiopoietin-1 plays a unique collabo-
rative and sequential role with VEGF.
Localization of Angiopoietin-1
in Developing Embryos
To obtain insight into the possible role of Angiopoie-
tin-1 during vascular development, its expression in de-
veloping embryos was examined by in situ hybridization.
To compare the distribution of Angiopoietin-1 with the
distribution of endothelial cells, the in situ hybridization
analysis was performed on parallel sections with an en-
dothelial-specific probe. (Although both TIE1 and TIE2
Figure 4. Biochemical Characterization of Angiopoietin-1 probes were used to detect endothelial cells, only hy-
(A) Molecular weight and glycosylation of Angiopoietin-1. Superna- bridizations with TIE1 are depicted because they pro-
tants from mock-transfected or Angiopoietin-1–transfected COS vided better images.) Earlier in development, at E9 to
cells were treated with PNGase-F and Western blotted with an anti-
E11, Angiopoietin-1 is found most prominently in thebody to Angiopoietin-1. Deglycosylation reduces the apparent mo-
heart myocardium surrounding the endocardium (Surilecular weight of Angiopoietin-1 from 70 kDa to the size predicted
et al., 1996), consistent with findings that the primaryfrom the amino acid sequence, 55 kDa.
(B) Binding of TIE2 receptors by cloned Angiopoietin-1. Angiopoie- defects in the developing vasculature of mice lacking
tin-1–containing COS cell supernatants were assayed for binding either TIE2 (Sato et al., 1995) or Angiopoietin-1 (Suri
activity to BIAcore sensor chips to which TIE2-Fc, TIE1-Fc, or TrkB- et al., 1996) involve endocardial branching and folding.
Fc were immobilized. In each case, excess soluble TIE2-Fc, TIE1-
Later in development, Angiopoietin-1 becomes muchFc, or TrkB-Fc was added to assess the specificity of binding. RU,
more widely distributed, most often in the mesenchymeresonance units.
surrounding developing vessels, in close association(C) Scatchard analysis of binding of Angiopoietin-1 to TIE2-Fc. (In-
set) Binding data plotted in Scatchard format. BOUND is given in with endothelial cells (Figures 6A and 6B). For example,
CPM 3 1023, and BOUND/FREE is given in CPM 3 1022/nM. in E13 embryos, Angiopoietin-1 could be detected in
(D) Competable activation of TIE2 receptors by cloned Angio- the vicinity of the intersegmental vessels (Figures 6C
poietin-1 in ABAE cells. ABAE cells were untreated or treated with
and 6D), in mesenchyme surrounding several vessels inconditioned media from either mock-transfected or Angiopoietin-
the peritoneum (Figures 6E and 6F), and in the devel-1–transfected (z125 ng/ml) COS cells and then assayed for tyrosine
oping eye adjacent to developing vasculature (Figuresphosphorylation of TIE2. Phosphorylation activity was blocked by
the addition of excess soluble TIE2-Fc but not TrkB-Fc. 6G and 6H); in all cases, signals with the TIE1 probe
(E) Activation of TIE2 receptors by cloned Angiopoietin-1 in human are much more distinct and punctate since they reflect
endothelial cells. Four human endothelial cell types (HUCEC, HAEC, detection of endothelial cells themselves, whereas
HMVEC, and HUVEC) were treated with conditioned media from
those with Angiopoietin-1 are more diffuse owing toeither mock-transfected or Angiopoietin-1–transfected COS cells
signal in surrounding mesenchyme.and then assayed for tyrosine phosphorylation of TIE2 receptors.
The embryonic expression patterns of Angiopoietin-1Ang1, Angiopoietin-1; IP, immunoprecipitation.
suggest that it plays a particularly important role in the
heart early in development and an increasingly wide-(Figure 5D, inset). We transfected this chimeric receptor
spread role as the rest of the vasculature matures.into MG87 fibroblasts, which display proliferative or sur-
vival responses following activation of many introduced
receptor tyrosine kinases (e.g., Glass et al., 1991); con- Discussion
trol cells were transfected with an expression vector
containing full-length TrkC. Both TrkC/TIE2 cells and We have previously shown that a “single-cell” expres-
sion cloning technique could be used for the efficientTrkC cells possess endogenous fibroblast growth factor
(FGF) receptors and proliferate similarly in response to isolation of membrane-bound ligands (Davis et al.,
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Figure 5. Lack of Proliferative Effects of TIE2
Activation in Endothelial Cells and in Fibro-
blasts
(A and B) Effects of FGF and Angiopoietin-1
on the proliferation of endothelial cells. HU-
VEC cells were treated with the indicated
amounts of FGF or Angiopoietin-1 and as-
sayed for proliferative activity. Angiopoie-
tin-1 was provided as conditioned media of
Angiopoietin-1–transfected COS with known
amounts of Angiopoietin-1; similar amounts
of conditioned media from mock-transfected
COS cells producedno effects on HUVEC cell
proliferation (data not shown).
(C and D) Effects of activation of the TIE2
kinase domain in fibroblasts. MG cells ectopi-
cally expressing either TrkC or TrkC/TIE2
chimera were treated with the indicated
amounts of FGF or NT3 and assayed for pro-
liferative activity. (Inset) Induction of tyrosine
phosphorylation of the TrkC/TIE2 chimera by
NT3, indicating that the chimeric receptor is
functional.
1994). This method provided considerable simplification responsible for assembling the fibrinogen-like domain
into some type of multimeric structure. Preliminary re-over iterative panning methods or techniques based on
sults (data not shown) indicate that this possibility isconstruction of pooled libraries, which entails screening
indeed the case. It will be relevant to determine theof individual pools followed by subdivision and re-
precise structure of Angiopoietin-1, to identify the por-screening of positive pools. Here we have extended
tions of it that are required for binding to TIE2, and tothe single-cell method to include secreted ligands, in
determine whether multimeric structure is necessary fora method we have termed secretion-trap expression
binding or activation. Because some proteins withcloning, thus providing an alternative route to the more
coiled-coil structure are found as heteromultimers oftime-consuming traditional approaches to this difficult
similar proteins rather than as homomultimers (e.g., fi-problem. We describe application of secretion-trap ex-
brinogen [Doolittle, 1984]), the possibility exists that An-pression cloning for the cloning of a novel secreted
giopoietin-1 can also form heteromeric structures withligand for the TIE2 receptor. We anticipate that this
other, closely related proteins; indeed, several such rela-method may be useful not only for the cloning of se-
tives of Angiopoietin-1 have been identified (P. F. J. etcreted ligands for other orphan receptors but also for
al., unpublished data). Different combinations of Angio-the identification of interacting partners for the many
poietin-1–related molecules may have different receptorsecreted proteins of unknown function currently being
specificities.discovered in large sequencing projects.
In contrast to previously characterized angiogenic
The structure of Angiopoietin-1 is unlike that of any
factors such as VEGF and FGF, Angiopoietin-1 is, under
other angiogenic factor or any other factors that bind
the conditions tested here, unable to elicit some of the
to receptor tyrosine kinases. Numerous proteins are responses that are typical of angiogenic factors. Appar-
known to possess domains resembling the C-terminal ently, Angiopoietin-1 serves some function other than
domain of fibrinogen, but in most cases little is known proliferation or tubule formation in endothelial cells. Be-
about the functions of these proteins. It is noteworthy cause vascular development evidently is a complex,
that all known examples of this type of protein have the multistep process that requires appropriate formation
fibrinogen-like domain at the C-terminus and that most and integration of the vasculature into its surrounding
are accompanied by N-terminal domains that have tissue, it would not be surprising that some factors might
coiled-coil structure (one exception is the ficolins, which regulate aspects of endothelial maturation that occur
have collagen-like N-terminal regions); it is not known after the initial stages of proliferation and tubule forma-
whether these shared structures form the basis for some tion. The expression of Angiopoietin-1 in the immediate
common functional theme. However, it is known that vicinity of developing blood vessels implicates this li-
coiled-coil regions typically are involved in the assembly gand in processes that are important for vascularization.
of the protein into multimeric structures; of note, the The later expression of TIE2 as compared to that of the
collagen-like N-terminal region of ficolin is also thought VEGF receptors (Dumont et al., 1995), together with our
to be involved in multimerization. It seems reasonable findings that Angiopoietin-1 expression seems to be-
come more widespread as development proceeds, isthat the coiled-coil domain of Angiopoietin-1 may be
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(e.g., Kaipainen et al., 1994), Angiopoietin-1 may provide
a means for specifically targeting tumor vasculature, for
example by conjugating it to a cytotoxin, as has been
suggested for VEGF (Burrows and Thorpe, 1994). In con-
trast to clinical situations in which attacking neovascu-
larizing endothelia might be desirable, there are situa-
tions in which it would be useful to promote angiogenic
processes, such as to induce collateral vascularization
in an ischemic heart or limb (Ferrara et al., 1995). Precise
understanding of the biologic roles of Angiopoietin-1
and its relatives and of how they may collaborate with
members of the VEGF family may lead to novel and
therapeutically significant strategies for promoting or
inhibiting neovascularization.
Experimental Procedures
Cell Culture and Production of Conditioned Media
SHEP1–1 cells were obtained from ATCC. C2C12ras cells were de-
rived from C2C12 cells by stable transfection with an expression
plasmid containing the ras oncogene. Cells were grown in defined
medium without added serum, and conditioned media were har-
vested and clarified by centrifugation. These media were brought
to 1 mM phenylmethylsulfonyl fluoride and 0.14 U/ml aprotinin, con-
centrated approximately 10-fold with 3000 MWCO membranes (Ami-
con), and stored at 2808C, as previously described (Stitt et al., 1995).
Production and Purification of Receptor-Fc Fusion Proteins
The ectodomains of each of TIE2, TIE1, and TrkB were fused to the
hinge, CH2, and CH3 regions of human IgG1 via a bridging sequence
Figure 6. In Situ Analysis of Angiopoietin-1 Gene Expression in De- (glycine–proline–glycine) as previously described (Davis et al., 1994).
veloping Embryos The fusion proteins were produced according to standard protocols
in Sf-21AE cells infected with baculovirus vectors bearing the re-(A, C, E, and G) were probed with TIE1 to localize endothelial cells.
spective fusion constructs (O’Reillyet al., 1992). Recombinant fusion(TIE2 in situ analyses,of inferior quality and thus not shown, revealed
proteins were then purified by protein A–Sepharose (Pharmacia)similar staining patterns.) (B, D, F, and H) were probed with Angio-
chromatography.poietin-1.
(A and B) Saggital cross section of rat embryos showing general
correlation between endothelial cells and Angiopoietin-1 expression BIAcore Analysis
in surrounding mesenchyme. Binding activity measured by use of BIAcore biosensor technology
(C and D) Enlargement of lower left insets in (A) and (B), highlighting (Pharmacia Biosensor) was performed essentially as previously de-
expression of Angiopoietin-1 in the vicinity of the intersegmental scribed (Stitt et al., 1995); specific binding to the TIE2 surface was
vessels. determined by incubating the samples with 25 mg/ml of TIE2-Fc,
(E and F) Enlargement of upper right insets in (A) and (B), highlighting TIE1-Fc, or TrkB-Fc prior to assay.
expression of Angiopoietin-1 in mesenchyme surrounding several
vessels (asterisks) in the peritoneum. Expression Cloning
(G and H) Expression of Angiopoietin-1 in the developing eye, adja- cDNA libraries of SHEP1–1 and C2C12ras cells were constructed
cent to developing vasculature. in the expression vector pJFE14 as described (Davis et al., 1994).
COS-7 cells were transfected with the libraries (1 mg/100 mm dish).
Two days after transfection, cells were washed with PBS and thenconsistent with the notion that Angiopoietin-1 plays an
fixed with PBS/1.8% formaldehyde for 15 min. Cells were then per-angiogenic role later and distinct from that of VEGF.
meabilized and blocked with assay buffer (PBS/10% calf serum)
Indeed, the findings of our accompanying study (Suri et containing 0.1% Triton X-100 for 15 min. Cells were then treated
al., 1996), in which embryos lacking Angiopoietin-1 were with assay buffer containing 1 mg/ml TIE2-Fc for 30 min. After two
analyzed for their vascular defects, are consistent with PBS washes, cells were incubated with assay buffer containing
alkaline phosphatase–conjugated goat anti-human antibodies forthis notion. The availability of a recombinant ligand for
30 min. After two additional PBSwashes, substrate buffer containingTIE2 will make it possible to investigate more directly
NBT/BCIP and 1 mM levamisole was added, and development wasthe functions of the TIE2 receptor in vivo and to develop
allowed to proceed until positive cells could be recognized over thein vitro systems in which the role of Angiopoietin-1 can
background. Development time must be determined empirically for
be revealed and studied. This work will be relevant not different types of receptor-Fc protein. Dishes were scanned for
only for understanding vascular development, but also, positively stained cells. Positive cells were scraped from the dish
since the TIEs mark the earliest of hemopoietic precur- and treated with a buffer containing 100 mM EDTA, 10 mM Tris (pH
8), 0.1% SDS, and 100 mg/ml proteinase K at 558C overnight. Sam-sors (Iwama et al., 1993; Batard et al., 1996; Hashiyama
ples were extracted with phenol/chloroform and ethanol precipi-et al., 1996), for understanding the role of the TIEs in
tated with carrier tRNA. Samples were resuspended in 5 ml of water,hemopoiesis.
and portions of this were used for electroporation of electrocompe-
Angiopoietin-1 may also have potential therapeutic tent bacteria. After electroporation the recovered bacterial cell sus-
utility independent of its usual biologic functions. Be- pension was either cultured overnight or plated on ampicillin plates
cause TIE2 apparently is upregulated during the patho- to produce individual colonies. Minipreps arising from cultures or
derived by culturing individual colonies were transfected into COSlogic angiogenesis that is requisite for tumor growth
Cell
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cells and then assayed as described above for the presence of TIE2- In Situ Analysis
Fresh-frozen E13.5 rat embryos were sectioned by cryostat andFc–staining cells.
probed with 35S-labeled cRNAs as described (Valenzuela et al.,
1993). Probes were, for TIE1, a 1.3 kb fragment of rat TIE1 spanningBiochemical Analysis
the last 309 codons and 375 bp of 39 untranslated sequence, andTo identify Angiopoietin-1 on Western blots, antisera were raised
for Angiopoietin-1, a 770 bp fragment of rat Angiopoietin-1 spanningagainst a synthetic peptide (NQRRNPENGGRRYNRIQHGQ) derived
the last 253 codons and 12 bp of 39 untranslated sequence. Sectionsfrom the N-terminal region of Angiopoietin-1. These antisera were
were immersed in radiographic emulsion (NTB-2, Kodak) and ex-affinity purified with the same peptide. Supernatants from COS cells
posed for 5–10 days.transfected with Angiopoietin-1 were treated with PNGase-F (New
England Biolabs) according to the manufacturer’s instructions and
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